Hengrui Pharma Reports No Share Capital Changes for May 2026; H-Share Public Float Stands at 3.89%

Bulletin Express06-02

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 31 May 2026, confirming that both authorised and issued share capital remained unchanged during the month.

Authorised / registered capital • H-shares: 0.26 billion shares at RMB 1 par value, unchanged from April 2026. • A-shares: 6.38 billion shares at RMB 1 par value, unchanged. • Total authorised capital: RMB 6.64 billion.

Issued shares and treasury position • H-shares in issue: 0.26 billion; no treasury shares outstanding. • A-shares in issue: 6.37 billion; treasury shares: 6.90 million. • No new shares were issued, repurchased, or cancelled in either class during May.

Public-float compliance • H-share public float was 3.89%, with a market value of HK$17.56 billion, exceeding the Main Board’s HK$1 billion threshold and confirming compliance with Listing Rule 19A.28D(1).

Employee share schemes • Up to 6.90 million A-shares remain available for transfer under the company’s 2022–2025 A-Share Employee Stock Ownership Schemes; no transfers occurred in May.

No outstanding share options, warrants, or convertible securities were reported, and no other share movements took place during the month.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108847328?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 16:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108847328","market":"hk","top_or_hot":-1,"title":"Hengrui Pharma Reports No Share Capital Changes for May 2026; H-Share Public Float Stands at 3.89%","media":"Bulletin Express","content":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 31 May 2026, confirming that both authorised and issued share capital remained unchanged during the month.</p>\n<p>Authorised / registered capital  \n• H-shares: 0.26 billion shares at RMB 1 par value, unchanged from April 2026.  \n• A-shares: 6.38 billion shares at RMB 1 par value, unchanged.  \n• Total authorised capital: RMB 6.64 billion.</p>\n<p>Issued shares and treasury position  \n• H-shares in issue: 0.26 billion; no treasury shares outstanding.  \n• A-shares in issue: 6.37 billion; treasury shares: 6.90 million.  \n• No new shares were issued, repurchased, or cancelled in either class during May.</p>\n<p>Public-float compliance  \n• H-share public float was 3.89%, with a market value of HK$17.56 billion, exceeding the Main Board’s HK$1 billion threshold and confirming compliance with Listing Rule 19A.28D(1).</p>\n<p>Employee share schemes  \n• Up to 6.90 million A-shares remain available for transfer under the company’s 2022–2025 A-Share Employee Stock Ownership Schemes; no transfers occurred in May.</p>\n<p>No outstanding share options, warrants, or convertible securities were reported, and no other share movements took place during the month.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hengrui Pharma Reports No Share Capital Changes for May 2026; H-Share Public Float Stands at 3.89%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHengrui Pharma Reports No Share Capital Changes for May 2026; H-Share Public Float Stands at 3.89%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-02 16:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 31 May 2026, confirming that both authorised and issued share capital remained unchanged during the month.</p>\n<p>Authorised / registered capital  \n• H-shares: 0.26 billion shares at RMB 1 par value, unchanged from April 2026.  \n• A-shares: 6.38 billion shares at RMB 1 par value, unchanged.  \n• Total authorised capital: RMB 6.64 billion.</p>\n<p>Issued shares and treasury position  \n• H-shares in issue: 0.26 billion; no treasury shares outstanding.  \n• A-shares in issue: 6.37 billion; treasury shares: 6.90 million.  \n• No new shares were issued, repurchased, or cancelled in either class during May.</p>\n<p>Public-float compliance  \n• H-share public float was 3.89%, with a market value of HK$17.56 billion, exceeding the Main Board’s HK$1 billion threshold and confirming compliance with Listing Rule 19A.28D(1).</p>\n<p>Employee share schemes  \n• Up to 6.90 million A-shares remain available for transfer under the company’s 2022–2025 A-Share Employee Stock Ownership Schemes; no transfers occurred in May.</p>\n<p>No outstanding share options, warrants, or convertible securities were reported, and no other share movements took place during the month.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1108847328","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108847328","pubTimestamp":1780388650,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 31 May 2026, confirming that both authorised and issued...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"恒瑞医药报告2026年5月股本无变化；H股公众持股量3.89%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 31 May 2026, confirming that both authorised and issued share capital remained unchanged during the month.\nAuthorised / registered capital  \n• H-shares: 0.26 billion shares at RMB 1 par value, unchanged from April 2026.  \n• A-shares: 6.38 billion shares at RMB 1 par value, unchanged.  \n• Total authorised capital: RMB 6.64 billion.\nIssued shares and treasury position  \n• H-shares in issue: 0.26 billion; no treasury shares outstanding.  \n• A-shares in issue: 6.37 billion; treasury shares: 6.90 million.  \n• No new shares were issued, repurchased, or cancelled in either class during May.\nPublic-float compliance  \n• H-share public float was 3.89%, with a market value of HK$17.56 billion, exceeding the Main Board’s HK$1 billion threshold and confirming compliance with Listing Rule 19A.28D(1).\nEmployee share schemes  \n• Up to 6.90 million A-shares remain available for transfer under the company’s 2022–2025 A-Share Employee Stock Ownership Schemes; no transfers occurred in May.\nNo outstanding share options, warrants, or convertible securities were reported, and no other share movements took place during the month.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108847328","isCrawlerRequest":true}